Cytek Biosciences, Inc. (NasdaqGS:CTKB) is looking for M&A. Patrik Jeanmonod, Chief Financial Officer said, "We will continue to invest in our core business as it relates to new project and innovation while remaining opportunistic in the M&A environment and focusing on growth in all key areas".
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.2 USD | -2.67% | +9.54% | -32.02% |
Mar. 20 | Cytek Biosciences Insider Sold Shares Worth $269,600, According to a Recent SEC Filing | MT |
Mar. 19 | Cytek Biosciences Appoints William McCombe as CFO, Reaffirms 2024 Guidance | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.02% | 836M | |
+7.62% | 219B | |
+6.70% | 183B | |
+11.94% | 132B | |
+24.60% | 106B | |
-2.66% | 62.09B | |
+4.81% | 50.88B | |
+11.55% | 50.8B | |
-1.09% | 40.64B | |
+26.82% | 31.59B |
- Stock Market
- Equities
- CTKB Stock
- News Cytek Biosciences, Inc.
- Cytek Biosciences Seeks M&A